Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
Assessment of the Role of Serum FSH Monitoring During Ovarian Stimulation and Identification of an Optimal Range for Expected Normal Responders
ART Fertility Clinics LLC
150 participants
Dec 16, 2024
OBSERVATIONAL
Conditions
Summary
This study examines if monitoring serum Follicle Stimulation Hormone (FSH) levels can predict oocyte yield and progesterone levels, considering factors like age, baseline FSH, Antral Mullerian Hormone (AMH), antral follicle count, body weight, kidney function, and urinary FSH. The aim is to find a minimum FSH level that ensures optimal ovarian response and enables tailored FSH dosages for better outcomes.
Eligibility
Inclusion Criteria6
- regular 21 - 35 days cycles
- BMI between 19 - 30 kg/m2
- serum AMH level between 1.5 to 3 ng/ml
- a total antral follicle count between 10 to 24
- endogenous early follicular phase serum FSH level <10 IU/L
- normal glomerular filtration rate
Exclusion Criteria8
- hypogonadotropic hypogonadism
- history of ovarian surgery
- permanent ovarian cysts of any form
- older than 39 years
- abnormal thyroid stimulating hormone (TSH)
- renal disease
- elevated prolactin levels
- intake of oral contraceptives 3 months before stimulation start and estradiol pretreatment will be excluded
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06572930